Correspondence 0001493152-23-003660 from Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc.
Date: Feb. 6, 2023 · CIK: 0001716166 · Accession: 0001493152-23-003660

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-269453

Date

Feb. 6, 2023

Author

Chief

Form

CORRESP

Company

Vivos Therapeutics, Inc.

Letter

VIA EDGAR Division of Corporation Finance Attention: Margaret Schwartz Re: Vivos Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-269453 Filed January 30, 2023

Dear Ms. Schwartz:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Vivos Therapeutics, Inc. (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. on Wednesday, February 8, 2023 (the “Effective Time”). The Company hereby grants to Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP the authority to communicate to the staff of the U.S. Securities and Exchange Commission one or more requests for any potential deferral of the Effective Time.

Very
truly yours,
/s/
R. Kirk Huntsman

Show Raw Text

CORRESP
1
filename1.htm

Vivos
therapeautics, Inc.

7921
Southpark Plaza, Suite 210

Littleton,
Colorado 80120

February
6, 2023

VIA
EDGAR

U.S.
SECURITIES AND EXCHANGE COMMISSION

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

Attention:
Margaret Schwartz

    Re:
    Vivos
    Therapeutics, Inc.

    Registration
    Statement on Form S-1

    File
    No. 333-269453

    Filed
    January 30, 2023

Dear
Ms. Schwartz:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Vivos Therapeutics, Inc. (the “Company”) hereby
requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m.
on Wednesday, February 8, 2023 (the “Effective Time”). The Company hereby grants to Lawrence A. Rosenbloom, Esq.
of Ellenoff Grossman & Schole LLP the authority to communicate to the staff of the U.S. Securities and Exchange Commission one
or more requests for any potential deferral of the Effective Time.

    Very
    truly yours,

    /s/
    R. Kirk Huntsman

    R.
    Kirk Huntsman

    Chief
    Executive Officer

SecProbe.io